Navigation Links
Amarin Announces Completion of the First Tranche of $60 Million Private Placement
Date:5/22/2008

t that they use words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or events. Among the factors that could cause actual results to differ materially from those described or projected herein are the following: Amarin's ability to maintain sufficient cash and other liquid resources to meet its operating and debt service requirements; the success of Amarin's research and development activities; decisions by regulatory authorities regarding whether and when to approve Amarin's drug applications, as well as their decisions regarding labeling and other matters that could affect the commercial potential of Amarin's products; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the success with which developed products may be commercialized; competitive developments affecting Amarin's products under development; the effect of possible domestic and foreign legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including under Medicaid and Medicare in the United States, and involuntary approval of prescription medicines for over-the-counter use; Amarin's ability to protect its patents and other intellectual property; claims and concerns that may arise regarding the safety or efficacy of Amarin's product candidates; governmental laws and regulations affecting Amarin's operations, including those affecting taxation; risks relating to the Company's ability to maintain its Nasdaq listing; general changes in International Financial Reporting Standards; and growth in costs and expenses. A further list and description of these risks, uncertainties and other matters can be found in Amarin's Form 20-F for the fiscal year ended December 31, 2007, filed with the SEC on May 19, 2008.


'/>"/>
SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amarin Announces Financial Results for Fourth Quarter and Full Year 2007
2. Amarin Secures Global Intellectual Property Rights for Lipid Programs
3. Amarin Appoints Dr. William Mason as Lead Independent Director
4. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
5. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
6. Amarin Signs Agreement to Acquire Ester Neurosciences
7. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
8. Amarin Announces Initiation of Cardiovascular Development Strategy
9. Amarin to Present at 4th Annual Bio Investor Forum
10. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
11. AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , August 28, 2015 ... Product (Media, Sera, Cryogenic Storage Systems, Thawing Equipment, Alarms), ... Regenerative Medicine, Clinical Trials), End User - Global Forecast ... is expected to reach USD 3,731.03 Million by 2020 ... CAGR of 11.65% between 2015 and 2020. ...
(Date:8/28/2015)... NY (PRWEB) , ... August 28, 2015 , ... Since the initial launch of FireflySci ... their quirky humor and excellent customer service. Images such as the Fonz in a ... to add some flavor to the humdrum spectroscopy field. , FireflySci is proud ...
(Date:8/27/2015)... Aug. 27, 2015 The National Necrotizing ... eyes—and life—were saved by doctors at Vanderbilt University Hospital ... NNFF, NovaBay Pharmaceuticals and Dr. John Crew , ... at Seton Medical Center in Daly City, ... a breakthrough approach, pioneered by Dr. Crew, that had ...
(Date:8/27/2015)... ... , ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately ... for the three years through 2014. Being named to the Inc. 5000 list designates ... country. , “We are thrilled to make the Inc. 5000 list for 2015,” ...
Breaking Biology Technology:Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... its Construction Unit, aims to increase the efficiency, reduce ... solutions for contaminated sites and for building development itself. ... and currently scientific work is being undertaken which shows ... for the recovery of contaminated soils. At present the ...
... Corporation (Nasdaq: DNDN ) today announced the ... the impact of labeled and unlabeled use of PROVENGE® ... prostate cancer. This panel was convened as a part ... by the Centers for Medicare and Medicaid Services (CMS). ...
... Session ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
Cached Biology Technology:Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence 2Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence 3Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 2Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 3Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 4Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 5Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 6Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 7Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 8Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 9Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 10
(Date:7/31/2015)... -- Die 10. internationale Konferenz zu Genomik (ICG-10, ... findet vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ... die ICG weltweit zu einem der einflussreichsten jährlichen ... der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
(Date:7/31/2015)... 31, 2015 The 10 th International Conference ... BGI from October 22-25, 2015, in Shenzhen , ... is celebrating its 10 th anniversary this year. Since its ... most influential annual meetings in the ,omics, fields, and is ... ICG-10 focuses on recent breakthroughs and advances ...
(Date:7/27/2015)... July 27, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Huawei has selected the ... for its stylish smartwatch. Huawei chose the state-of-the-art ... low power and highly responsive human interface qualities ... designers also required a classic round watch face ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... climate change causes changes in the species composition of ... also to fish populations. Previous studies demonstrating a link ... entirely on statistical data. However, in order to estimate ... understanding of the effect of water temperature on the ...
... Researchers have made a breakthrough by detecting the electrical ... takes them a step closer to both seeing the ... test drugs. , To stay alive, individual biological ... their cell membranes. This flow produces an electrical current ...
... a major risk factor for Alzheimer's disease puts out the welcome ... to be more active in the brain compared to other forms ... Neurobiology of Aging, add some scientific heft to the idea, long ... bringing about Alzheimer's disease. , The work links a form of ...
Cached Biology News:How fish species suffer as a result of warmer waters 2A new study of living cells could revolutionize the way we test drugs 2Cold sore virus might play role in Alzheimer's disease 2Cold sore virus might play role in Alzheimer's disease 3Cold sore virus might play role in Alzheimer's disease 4
See product name for description....
... excluding l-[U-14C]methionine, 1.85 MBq, 50 uCi. ... > 1.85 GBq/mg atom carbon, ... Mixture of Ala, Arg, Asp, Glu, ... Pro, Ser, Thr, Tyr and Val.1.85 ...
Request Info...
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
Biology Products: